ADRA2A and *IRX1* are putative risk genes for Raynaud's phenomenon

Sylvia Hartmann[1], Summaira Yasmeen[1], Benjamin M Jacobs[2], Spiros Denaxas[3,4,5,6], Munir Pirmohamed[7], Eric R. Gamazon[8], Mark J. Caulfield[9], Genes & Health Research Team*, Harry Hemingway[3,4,6], Maik Pietzner[1,10,11,a], Claudia Langenberg[1,10,11,a]

[1]Computational Medicine, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
[2]Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
[3]Institute of Health Informatics, University College London, London, UK
[4]Health Data Research UK, London, UK
[5]British Heart Foundation Data Science Centre, London, UK
[6]National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK
[7]Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalised Medicine, University Liverpool, Liverpool, UK, Liverpool, UK
[8]Division of Genetic Medicine and Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN 37232, USA
[9]William Harvey Research Institute, Queen Mary University of London, London, UK
[10]MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
[11] Precision Healthcare University Research Institute, Queen Mary University of London, London, UK
*A list of authors and their affiliations appears at the end of the paper
[a]these authors jointly supervised the work

Correspondence

Prof Claudia Langenberg (claudia.langenberg@bih-charite.de)
Dr Maik Pietzner (maik.pietzner@bih-charite.de)

Abstract

Raynaud's phenomenon (RP) is a common vasospastic disorder that causes severe pain and ulcers, but despite its high reported heritability, no causal genes have been robustly identified. We conducted a genome-wide association study including 5,147 RP cases and 439,294 controls, based on diagnoses from electronic health records, and identified three unreported genomic regions associated with the risk of RP ($p<5\times10^{-8}$). We prioritized *ADRA2A* (rs7090046, odds ratio (OR) per allele: 1.26; 95%-CI: 1.20-1.31; $p<9.6\times10^{-27}$) and *IRX1* (rs12653958, OR: 1.17; 95%-CI: 1.12-1.22, $p<4.8\times10^{-13}$) as candidate causal genes through integration of gene expression in disease relevant tissues. We further identified a likely causal detrimental effect of low fasting glucose levels on RP risk (r_G=-0.21; p-value=2.3×10^{-3}), and systematically highlighted drug repurposing opportunities, like the antidepressant mirtazapine. Our results provide the first robust evidence for a strong genetic contribution to RP and highlight a so far underrated role of α_{2A}-adrenoreceptor signalling, encoded at *ADRA2A*, as a possible mechanism for hypersensitivity to catecholamine-induced vasospasms.

Introduction

Raynaud's phenomenon (RP) is a common episodic, vasospastic disorder that affects 2-5% of the population and can severely affect an individual's quality of life by causing pain or even ulcers[1–3]. RP typically manifests with bi- or triphasic colour change in fingers and toes because of vasospasms in arteriovenous anastomoses responsible for thermoregulation, that can be triggered by cold or emotional stress[4]. The causes for the more common form of primary RP are largely unknown[4,5], while secondary RP is diagnosed as a consequence of connective tissue diseases, like systemic lupus erythematosus (SLE) or systemic sclerosis (SSc), or triggered by use of drugs such as beta-blockers. Management of RP is predominantly limited to the avoidance of triggers and evidence for medical treatment is generally weak. Repurposed vasodilators are the first line treatment if pharmacological intervention is required due to progressive frequency of vasospastic attacks[6], although only calcium channel blockers have so far been shown to lead to a significant and reproducible reduction in the frequency of vasospastic attacks[7]. However, use of systemic drugs for localized symptoms puts patients at risk of generalised adverse effects, such as hypotension. While there are now trials investigating local application of botulinum toxin to mitigate vasospastic effects with early promising results[8], a better understanding of the underlying mechanisms is needed to develop safe and effective treatments.

RP is highly heritable with estimates of 55-64% being reported[9,10], but previous candidate gene studies[11,12], like at serotonin receptors[13], and an early, small (n=640 cases) genome-wide association study (GWAS)[14] failed to provide evidence for any robustly associated regions or genes. In-depth investigation and integration of detailed information from primary and secondary healthcare records with genetic array data now provides the opportunity to study under-investigated diseases with diagnostic specificity at unprecedented scale.

Here, we present the so far largest GWAS for RP including 5,147 cases in the UK Biobank cohort[15] and report two robust and strong ($p<4.8x10^{-13}$) novel loci. We highlight two independent disease mechanisms supported by those loci that challenge and advance our current understanding of primary RP, with *ADRA2A* highlighting the role of α_{2A}-adrenoreceptors and *IRX1* as a putative regulator of vasodilation by altering prostaglandin and/or bradykinin responsiveness.

Results

We identified a total of 5,147 RP cases and 439,294 controls of European descent included in the genetic analyses (**Supplementary Tab. 1** and **Supplementary Fig. 1**) based on collation and evidence of absence or presence of diagnostic codes from electronic health records (ICD-10 codes: I73.0, I73.00, I73.01; CTV3/Read2: G730., G7300, G7301, G730z, XE0VQ), including 2,185 prevalent cases and 2,962 incident cases. We followed the recommendation by Wigley *et al.*[4] to summarize all patients with a relevant code under the term RP (Raynaud's phenomenon) rather than Raynaud's syndrome.

Genome-wide association analysis

We identified a total of three genome-wide significant novel loci ($p<5.0\times10^{-8}$, minor allele frequency (MAF) 14.3%-31.1%) associated with RP (**Fig. 1** and **Tab. 1;** regional association plots in **Supplementary Fig. 2**). Two of which met a more stringent significance threshold ($p<1.0\times10^{-9}$; **Tab. 1**), which we consider as tier 1 findings of which one had previously been shown to increase the risk of myocardial infarction (rs12653958). All lead variants increased the risk for RP by ~20% per copy of the minor allele (**Tab. 1**) and resided in intergenic regions with no obvious functional variants in linkage disequilibrium (LD; $r^2>0.6$) and were of low predicted impact (range: 0.36 – 3.41). Despite the established sex-difference of RP, we did not find evidence that effects of any of the identified lead signals differed between men and women (all p-values for interaction > 0.05; **Supplementary Tab. 2**). We estimated a single nucleotide polymorphism (SNP)-based heritability on the liability scale of 7.7% (95%-CI: 4.8-10.6%, $p<2.4\times10^{-7}$) with little evidence of genomic inflation (LD-score intercept 1.01; **Supplementary Fig. 3**).

Tier	SNP	Chr	Position	Alleles	MAF	OR (95%-CI)	P value	Closest gene*
1	rs7090046	10	112860930	A/G	0.31	1.26 (1.20, 1.31)	9.58×10^{-27}	*ADRA2A*
1	rs12653958	5	4032849	A/G	0.30	1.16 (1.12, 1.22)	4.76×10^{-13}	*IRX1*
2	rs3094013	6	31434366	G/A	0.14	1.17 (1.11, 1.24)	9.73×10^{-9}	*MICB*

Table 1 Regional lead variants for the 8 loci significantly associated with Raynaud's phenomenon Tier = categorization whether genetic loci met a stringent Bonferroni threshold for significance (tier 1; $p<1.0\times10^{-9}$) or the standard genome-wide significance threshold (tier 2; $p<5.0\times10^{-8}$). N = 444,441, 5,147 cases and 439,294 controls. Chr = Chromosome; MAF = minor allele frequency; OR = odds ratio from logistic regression models; Alleles are given as effect allele/non-effect allele; *protein coding gene in italics

To evaluate whether genetic findings were specific for the development of RP or driven by associations with diseases leading to secondary RP, we performed sensitivity analyses based on a more stringent definition of primary RP (3,505 cases, 68.1%) that excluded potential secondary cases (see **Methods**). Effect estimates for both tier 1 loci were highly consistent in size and direction (**Supplementary Tab. 3**) and remained genome-wide significant ($p<1.4\times10^{-12}$ for both), indicating their potential role in the idiopathic origin of primary RP, whereas the association within the MHC region was attenuated.



Figure 1 Manhattan plot of genome-wide association results for Raynaud's phenomenon (5,147 RP cases and 439,294 controls**)** Distribution of RP-associated single nucleotide polymorphisms across the genome, -log10(P-values) from logistic regression models are plotted for each variant. The grey dashed line indicates the genome-wide significant threshold at $p=5x10^{-8}$. Regional sentinel variants at significant loci are highlighted with a diamond and the closest gene, if any, is annotated.

ADRA2A and *BBIP1* are likely effector genes at 10q25.2

The lead variant at this strongest locus, rs7090046, is located 24.1k bp downstream to *ADRA2A* and 181.9k bases downstream from *BBIP1* (**Fig. 2**) and Bayesian fine-mapping identified a 95%-credible set of only 4 variants (see **Methods**), comprising rs7090046, rs1343449, rs1343451, and rs7084501 with posterior inclusion probabilities (PIP) of 48.6%, 23.6%, 12.5% and 12.6% of the GWAS signal, respectively. Variant rs1343449 is a reported gene expression quantitative trait locus (cis-eQTL) for *ADRA2A* in artery tissue and statistical colocalization confirmed a shared genetic signal with RP with high confidence (tibial artery, posterior probability (PP) > 96%; **Fig. 2**), with the RP risk-increasing A-allele of rs7090046 being associated with higher *ADRA2A* expression (beta=0.28, $p=1.0x10^{-9}$). We also observed evidence of colocalization with *BBIP1* expression in the brain hippocampus and colon (PP> 98%; **Fig. 2** and **Supplementary Data 1**), with the A-allele being associated with lower *BBIP1* expression in brain hippocampus (beta=-0.37, $p=9.1x10^{-9}$), raising the possibility that variants in the credible set have pleiotropic, tissue-dependent effects in different directions.

ADRA2A encodes α_{2A}-adrenoreceptors, responsible for mediating response to stress in the central and peripheral autonomous nervous system[16], and vasoconstriction in response to catecholamine release in the small arteries and arterioles[17]. Our finding may imply that overstimulation or increased expression of α_{2A}-adrenergic receptors contributes to the vasospastic effects characteristic of RP and its symptoms, also in line with RP being an adverse effect of α_2-adrenergic agonists such as clonidine[4,18,19]. A possible role of *BBIP1*, in contrast, is less obvious. *BBIP1* encodes for a protein in the BBSome complex, which is involved in the signalling from and to cilia.

Investigating thousands of other outcomes from the GWAS catalog[20] and the Open Targets platform[21] in addition to phenome-wide analyses of UK Biobank ($p<10^{-6}$, see **Methods**), we observed no other significant associations for rs7090046 or its proxies ($r^2>0.6$), except for "specified peripheral vascular disease" in UK Biobank (OR 1.18, p-value 4.5×10^{-11}), a non-specific code that comprises, among other diseases, RP. These results suggest specificity of the mechanism underlying the genetic signal at 10q25.2 on RP.



Figure 2 Regional association plot at *ADRA2A/BBIP1*. Regional association plot for Raynaud's phenomenon (top), gene expression of *ADRA2A* in tibial artery (middle), and gene expression of *BBIP1* in hippocampus (bottom). *ADRA2A* and *BBIP1* have been prioritised as candidate causal genes based on statistical colocalization. Summary statistics from logistic regression models for RP are form the present study whereas summary statistics from linear regression models were obtained from GTEx v8[22]. Colouring of SNPs is based on linkage disequilibrium with the lead RP variant (rs7090046) at this locus. Numbers in brackets indicate posterior probabilities (PP) for a shared genetic signal with RP based on statistical colocalization.

144 ## *IRX1* is the likely effector gene at 5p15.33 and links to cardiovascular outcomes

145 We fine-mapped the second strongest signal at 5p15.33 to 24 variants with rs12653958 as the lead
146 SNP with a PIP of 6.4%. The credible set also covered rs11748327 (PIP=4.7%) that has been reported
147 as a cis-eQTL for *IRX1* in skeletal muscle[22]. Statistical colocalization further confirmed a shared genetic
148 signal between RP and *IRX1* expression in skeletal muscle and tibial artery with high (PP=99%) and
149 moderate (PP=47%) confidence, respectively (**Fig. 3**). The RP-increasing effect-allele of rs11748327 was
150 associated with higher expression of *IRX1* in skeletal muscle (beta=0.57, $p=1.1x10^{-22}$) and tibial artery
151 (beta=0.42, $p=5.7x10^{-11}$), suggesting that higher gene expression confers a higher risk for RP. *IRX1*
152 encodes for members of the homeobox containing genes which have been shown to be involved in
153 embryonic development and cellular differentiation[23]. The lead variant, rs12653958, at this locus tags
154 a cluster of variants (r^2=0.7-1.0) that has previously been reported to be associated with myocardial
155 infarction (MI)[24,25] and coronary artery disease (CAD)[26] among East Asian populations and is further a
156 cross-ancestral signal for red blood cell phenotypes[27,28]. In detail, the RP risk-increasing G-allele was
157 also associated with an increased risk for coronary artery disease (beta=-0.06; $p<1.8x10^{-8}$) in data from
158 the BioBank Japan[26]. The fact that this common variant (MAF_{EUR}=30.0%; MAF_{EAS}=22.3%) has not yet
159 been identified for MI or CAD in Europeans ($p= 1.61x10^{-7}$) despite much larger sample sizes
160 (n=181,522)[29], might point to the possibility of a yet to be identified gene-environment interaction or
161 other characteristics distinct to the East Asian cohorts that account for this observation.



Figure 3 Regional association plot at *IRX1*. Regional association plot for Raynaud's phenomenon (top), gene expression of IRX1 in skeletal muscle (middle), and gene expression of IRX1 in tibial artery (bottom). Summary statistics from logistic regression models for RP are form the present study whereas summary statistics from linear regression models were obtained from GTEx v8[22]. Colouring of SNPs is based on linkage disequilibrium with the lead RP variant (rs12653958) at this locus. Numbers in brackets indicate posterior probabilities (PP) for a shared genetic signal with RP based on statistical colocalization.

RP in individuals of South Asian ancestry

We aimed to test for replication and transferability of our European-centric results in 401 RP cases of British Bangladeshi and Pakistani ancestry from the Genes & Health cohort[30] (n=40,532), and observed directionally concordant results (rs11748327; OR=1.16, 95%-CI=0.99-1.37, p-value=0.06; *IRX1*) for one of the two strongest loci, while for the second one, rs7090046 (*ADRA2A*), the lead variant or suitable genetic proxies were not available. While we were underpowered to replicate the remaining signals due to low number of cases, we noted that the rare European variant rs7601792 (MAF=0.16%) was common among people of British Bangladeshi and Pakistani descent (MAF=12.7%) possibly indicating

177 an ancestry-specific signal. However, further studies with comparable numbers of RP cases are needed
178 to establish trans-ethnic and ethnic-specific risk variants for RP.

179 Genetic correlation between RP and other traits

180 We next tested for a shared genetic architecture (genetic correlation: r_G) between RP and known or
181 suspected risk factors and comorbidities with a vascular or immune origin/component like peripheral
182 artery disease (PAD) or COVID-19 (**Supplementary Data 2**). We observed that possible causes or
183 related disorders for RP, like migraine (r_G= 0.21, p=9.0x10^{-3}), PAD (r_G=0.38, p=2.1x10^{-3}), or SLE (r_G=0.33
184 p=1.0x10^{-3}) significantly (false discovery rate<5%) correlated when considering all RP patients, but
185 were strongly attenuated once we computed genetic correlations restricted to patients with primary
186 RP (**Supplementary Fig. 5, Supplementary Data 3**). In contrast, other significant correlations persisted
187 (p<0.05) when we restricted genetic correlation analysis to results based on patients with primary RP
188 (to which we refer to as *robust* in the following). This included significant inverse correlations with type
189 2 diabetes (r_G = -0.14, p=2.7x10^{-3}), fasting glucose (r_G = -0.21, p=0 p=2.3x10^{-3}), and a positive correlation
190 with HDL-cholesterol levels (r_G=0.13, p=9.2x10^{-4}) (**Supplementary Fig. 5**).

191 To distinguish whether genetic correlations represent causal directions from versus towards RP or are
192 due to shared risk factors that likely act independently on RP and correlated traits, we performed latent
193 causal variable analysis[31] (see **Methods**). Out of a total of six phenotypes with evidence for significant
194 genetic correlations, only SLE (genetic causality proportion (GCP)=0.75; p<1.7x10^{-4}) and fasting glucose
195 (GCP=0.77; p<5.21x10^{-15}) showed strong evidence for a causal genetic effect on RP risk, of which fasting
196 glucose but not SLE persisted in analyses considering only patients with primary RP (GCP=0.80;
197 p<1.3x10^{-16}). These results indicate that low fasting glucose levels may causally increase the risk for RP,
198 while frequent comorbidities of RP, like migraine, are likely explained by shared risk factors.

199 We then extended the targeted analysis by computing genetic correlations with 185 medical concepts
200 – 'phecodes', to gain a more comprehensive view on possible diseases that share a genetic architecture
201 with RP (see **Methods**; **Supplementary Data 4**). We observed 8 phecodes with significant, although
202 moderate, genetic correlations with RP (**Supplementary Data 4**), of which only the significant genetic
203 correlation with osteoporosis persisted when we restricted the analysis to patients with primary RP
204 (r_G=0.35, p<8.7x10^{-5}). However, none of the phenotypes showed evidence of a direct causal link
205 towards or from RP in latent causal variant analysis (see **Methods**; **Supplementary Tab. 4**).

206 From genes to druggable targets

207 We finally searched for putative druggable targets for RP based on the identified loci by cross-
208 referencing high-confidence gene assignments and functional interaction partners thereof[32] in the
209 Open Targets database[21] (see **Methods**). While we identified no link for drugs with known (genetic)
210 targets currently or previously in clinical trials for RP (e.g., phosphodiesterase inhibitors), we identified

a total of 211 drugs that target either directly (e.g., *ADRA2A*) or indirectly (e.g., *PTGS2*) gene products identified in our study (**Fig. 4** and **Supplementary Data 5**). More than 50 drugs had at least some affinity to α_{2A}-adrenergic receptors, although none did so specifically. Since we identified increased expression of α_{2A}-adrenergic receptors as a possible disease-causing mechanism, partially selective antagonists, such as the widely used antidepressant mirtazapine, might be promising candidates for repurposing. Among the drugs indirectly linked to RP-associated gene products, those counteracting vasoconstriction or promoting vasodilation have greatest repurposing potential. For example, drugs promoting prostaglandin (via *PTGER1* but not *PTGS2*) or bradykinin signalling (via *BDKRB2*) such as dinoprostone or labradimil, respectively, might exert beneficial effects. However, the indirect nature of the gene-drug-disease link for the latter (via altered *IRX1* expression) requires further functional follow-up to establish the precise underlying mechanism and effect directions.



Figure 4 Gene-Drug-Disease network for Raynaud's phenomenon. The network displays drug target information obtained from Open Targets[21] for 1) Raynaud's Phenomenon (RP; blueish area), 2) genes associated with RP in the present study (yellow), and 3) interacting genes (white) based on functional work[32].

Discussion

RP is a common but understudied disease with a high heritable component and identifying responsible genes can advance our understanding of the aetiology and eventually guide the development of treatment strategies. We identified, for the first time, two robust susceptibility loci. Through integration with gene expression data, we demonstrated that the strongest locus likely acts via increased expression of α_{2A}-adrenoreceptors in arterial tissue, augmenting the current concept of

232 predominantly α_{2C}-adrenoreceptors mediating the vasospasms seen in RP patients[4]. Increased
233 expression of the transcription factor *IRX1* in muscle, and possibly arterial tissue, may further alter
234 genes involved in prostaglandin and/or bradykinin sensing and production, providing a putative second
235 novel mechanism identified in our genetic study. We lastly observed no strong evidence for a shared
236 genetic architecture with suspected cardiovascular comorbidities for primary RP but did observe a
237 novel detrimental effect of low fasting plasma glucose that might help to guide primary RP
238 management.

239 Vasospastic attacks in RP have been repeatedly attributed to cold-induced activation of α_{2C}-
240 adrenoreceptors[4,18,33,34], but attacks also occur under thermoneutral conditions and selective,
241 pharmacological blocking of α_{2C}-adrenoreceptors did not mitigate symptoms in clinical trials[35]. An
242 observation that aligns with the absence of an effect of a strong cis-eQTL for *ADRA2C* (rs35729104),
243 encoding for α_{2C}-adrenoreceptors, on RP risk (OR=1.02, p=0.29) in our study. We, in contrast, provide
244 genetically anchored evidence that α_{2A}-adrenoreceptors play an underrated role further supported by
245 adverse drug reactions seen with α_{2A}-adrenoreceptor agonists (**Fig. 5**). More specifically, α_{2A}-
246 adrenoreceptors mediate arterial vasoconstriction, thrombus stabilization, and hypothermic effects
247 on body temperature[36,37]. Our results are in line with a vasoconstrictive role of α_{2A}-adrenoreceptors
248 under thermoneutral conditions[17] and subsequent RP risk and further support findings of a quantitively
249 stronger role of α_2-adrenoreceptors compared to α_1-adrenoreceptors during cold stress in RP
250 patients[38,39]. However, it might still be conceivable that both α_2-adrenoreceptors act in a context-
251 specific manner to induce vasospastic effects[19] or another mechanism partakes in cold-induced RP
252 attacks, since pharmacological inhibition of α_2-adrenergic receptors did blunt but not eliminate cold-
253 induced vasoconstriction[38].

254

255



Figure 5 Scheme of the key finding. In people without Raynaud's phenomenon (RP) stimulation of α_{2A}- and α_{2C}-adrenoreceptors contributes to vasoconstriction and lower blood flow. In patients with RP, blood flow is further reduced due to overexpression of α_{2A}-adrenoreceptors creating a state of hypersensitivity to catecholamine-release. Created with BioRender.com

Currently, RP is treated depending on its severity. For mild cases, avoidance of triggers like cold or emotional stress might be sufficient, but severe vasospastic attacks require pharmacological interventions with calcium channel blockers as first line response[6]. However, overall effectiveness of calcium channel blockers[5] or alternative vasodilatory medications such as angiotensin receptor blockers, selective serotonin reuptake inhibitors, or phosphodiesterase-5 inhibitors is limited[6,7]. Negative findings that overall align well with the absence of genetic evidence for those targets in our study. A staggering characteristic of the *ADRA2A* locus was the specificity in phenome-wide screens and comprehensive database lookups, which indicated a RP-specific effect. Such a characteristic may make the inhibition of the gene product, α_{2A}-adrenoreceptors, an interesting pharmacological target. This does not rule out that systemically administered antagonists might exert adverse effects, but inhibiting α_{2A}-adrenoreceptor activity in disease-relevant tissue, for example using topical solutions, might provide a safe and effective treatment option. There are already approved medications that target α_2-adrenoreceptor antagonistically like the widely prescribed antidepressant mirtazapine, but they lack specificity for α_{2A}-adrenoreceptor[36] and case reports described the occurrence or worsening of RP in two male patients under yohimbine treatment, another α_2-adrenoreceptor antagonist, for erectile dysfunction[40,41]. Clinical trials are needed to test whether treatment with mirtazapine, or topical solutions thereof, can indeed mitigate vasospastic attacks in patients with primary RP, also because an early study described relieved symptoms under methyldopa, a α_2-adrenergic agonist[42].

In addition to hypersensitivity to vasoconstrictive stimuli, missing vasodilation is the primary cause of persistent vasospasms in RP. We identified overexpression of *IRX1*, the second strongest signal for RP, in muscle cells and possibly tibial artery as a putative RP risk increasing mechanism. While little is

282 known about *IRX1* in general, a transfection study in gastric cancer cell lines identified several putative
283 target genes of *IRX1* with a role in vasoconstriction and vasolidation[43]. This included downregulation
284 of *PTGER1*, encoding the prostaglandin E2 receptor 1 (EP1) and upregulation of *PTGS2*, encoding
285 prostaglandin G/H synthase 2, as well as downregulation of *BDKRB2*, encoding bradykinin receptor B2.
286 Prostaglandin E2 (PGE_2) can induce both vasodilation and vasoconstriction depending on receptor
287 binding, with binding to EP1 inducing vasoconstriction in smooth muscle cells[44,45]. Downregulation of
288 *BDKRB2* in endothelial and smooth muscle cells, in turn, may blunt the vasodilative function of
289 bradykinin[46], in line with observations in RP patients treated with bradykinin[47,48]. A putative role of the
290 *IRX1* locus in vasodilation/vasoconstriction might also explain its association with cardiovascular
291 disease as described among people of East Asian descent[24–26]. Further experimental work will help
292 clarify this, and might also help to refine the application of prostaglandin or bradykinin analogues, as
293 vasodilators in RP[4].

294 Little is known about the causes of primary RP, and we provided evidence that genetic liability towards
295 low fasting glucose levels increases RP risk. A putative mechanism, however, remains elusive and we
296 did not observe evidence that other metabolic risk factors were causally associated with RP risk,
297 including BMI (**Supplementary Data 3**). Overexpression of α_{2A}-adrenoreceptors in pancreatic islet cells
298 has been postulated as a mechanism for diminished insulin secretion and postprandial hyperglycaemia
299 among carriers of risk alleles in *ADRA2A*[49]. However, the reported risk allele, rs553668, is only weakly
300 correlated (r^2=0.15) with our RP lead signal at the same locus and the same applies for the more
301 recently identified genome-wide significant finding[50]. Although likely via distinct genetic variants, both
302 diseases seem to share overexpression of *ADRA2A* as a common, but tissue-specific, disease
303 mechanism, and it is unclear whether overexpression of *ADRA2A* in pancreatic beta-cells also
304 contributes to fasting glucose levels. Conversely, hypoglycaemia exerts profound changes on the
305 vasculature, including vasoconstriction via increased adrenal catecholamine release to maintain blood
306 flow to the brain[51], that may in turn exaggerate hypersensitivity to catecholamines of arteriovenous
307 anastomoses in fingers and toes. However, a drop in body temperature following hypoglycaemia is
308 caused by cutaneous vasodilation, which might itself be a trigger for vasospastic effects in RP patients.
309 Even a role of β-adrenergic receptors might be conceivable, since beta-blockers can cause both,
310 hypoglycaemia[52] and RP[4]. A pragmatic consequence for people at RP risk, or even RP patients, might
311 be to avoid episodes of low plasma glucose levels.

312 While we identify eight loci robustly associated with RP, we did not find support for genes highlighted
313 by previous smaller scale and candidate gene studies. This included subthreshold findings from an
314 earlier GWAS[14] (*NOS1*, smallest p-value in *NOS1* region ± 500kb (p_{min}) = 2.6×10^{-3}) as well as candidate
315 gene studies for serotonin 1B (*HTR1B*; $p_{min}=6.8 \times 10^{-4}$) and 1E (*HTR1E;* $p_{min}=1.2 \times 10^{-5}$) receptors and the
316 beta subunit of the muscle acetylcholine receptor (*CHRNB1*; $p_{min}=1.3 \times 10^{-3}$)[13]. Our results therefore

317 highlight the need for large sample sizes, which are only now possible with the increased availability
318 of electronic health record linkage.

319 Our study has limitations that need to be considered in the interpretation of the results. Firstly, we
320 defined patients with RP based on billing codes from medical records of various sources which might
321 have missed patients with milder presentations and suffers from potential misclassification if patient
322 symptoms have been wrongly assigned to RP, in particular in the presence of disease that cause RP as
323 a secondary phenomenon. However, our conservative sensitivity analysis, excluding all patients with
324 potential known causes of RP revealed congruent findings and the associated loci have a clear
325 biological link towards RP pathology. Secondly, our study was exclusively comprised of participants of
326 European descent and low case numbers and poor imputation quality of the main locus did not permit
327 robust analysis in other ancestries, which is needed to achieve fair representation of different
328 ancestries in genomic studies and may reveal additional findings. Thirdly, while we were able to
329 replicate the association between *ADRA2A* expression in tibial artery and risk of RP in a small,
330 independent cohort (n=124 RP patients; OR=1.27; p = 0.0039) from the BioVU study[53], additional
331 efforts in large biobanks with linked primary care data are needed to further consolidate our findings.
332 Finally, while we assign putative candidate genes at two loci, more work is needed to improve gene
333 assignment pipelines to elucidate possible mechanism at other loci including rare variants with strong
334 effect sizes.

335 Our results advance the understanding of RP pathology by shifting the focus from a merely cold-
336 induced phenomenon to a clinical entity in its own right with a distinct genetic architecture. The
337 identification of *ADRA2A* and *IRX1* as candidate causal genes will further inform the development and
338 refinement of treatment strategies although more experimental work is needed.

339

340 ## Methods

341 ### United Kingdom Biobank (UKBB)

342 UK Biobank is a prospective cohort study from the UK which contains more than 500,000 volunteers
343 between 40 and 69 years of age at inclusion. The study design, sample characteristics and genome-
344 wide genotype data have been described in Sudow et al. and Bycroft et al.[15,54]. The UKBB was approved
345 by the National Research Ethics Service Committee North West Multi-Centre Haydock and all study
346 procedures were performed in accordance with the World Medical Association Declaration of Helsinki
347 ethical principles for medical research. We included 444,441 individuals in the GWAS for whom
348 inclusion criteria (given consent to further usage of the data, availability of genetic data and passed
349 quality control of genetic data) applied. Data from the UKBB were linked to death registries, hospital
350 episode statistics (HES) and primary care data.

351 ### RP case ascertainment

352 We used all available electronic health records, including primary (~45% of the population) and
353 secondary care, death certificates as well as participant's self-report to define RP cases. We manually
354 curated relevant codes for RP based on the different coding systems used (ICD-10 codes: I73.0, I73.00,
355 I73.01; CTV3/Read2: G730., G7300, G7301, G730z, XE0VQ) and flagged the first occurrence of a related
356 code in the records of a participant as the incidence date. We compared the date of the very first
357 record related to RP with the date of the baseline examination of the same participant to distinguish
358 between prevalent and incident RP. We followed the criteria from Wigley et al.[4] to differentiate
359 between primary and secondary RP. In detail, we classified each RP case as 'secondary' when patients
360 were either under beta-blocker treatment or had been diagnosed with one of the following diseases
361 prior or at the same time of their RP diagnosis: arteriosclerosis, carpal tunnel syndrome, systemic lupus
362 erythematosus, systemic sclerosis, polymyositis, dermatomyositis, Sjögren syndrome, hypothyroidism,
363 cryoglobulinemia, frostbite or other connective tissues diseases (**Supplementary Data 6**).

364 ### UKBB medication classification/ beta-blocker usage

365 During the baseline assessment self-reported regular medication use was recorded. Medication data
366 were categorized into 6,745 groups (Data field: 20003). 38 categories of the medication data were
367 identified manually to represent medication containing beta-blocker substances.

368 ### Demographic analysis

369 We performed χ^2-tests and analysis of variance to test for statistically significant differences in
370 demographic characteristics between controls and RP cases using standard implementations in R
371 (v4.1.2).

372 ## Genotyping, quality control and participant selection

373 Details on genotyping for UKBB have been reported in detail by Bycroft et al.[15]. Briefly, we used data
374 from the 'v3' release of UKBB containing the full set of Haplotype Reference Consortium (HRC) and
375 1000 Genomes imputed variants. We applied recommended sample exclusions by UKBB including low
376 quality control values, sex mismatch, and heterozygosity outliers. We defined a subset of 'white
377 European' ancestry by clustering participants based on the first four genetic principal component
378 derived from the genotyped data using a k-means clustering approach with k=5. We classified all
379 participants who belonged to the largest cluster and self-identified as of being 'white,' 'British', 'Any
380 other white background', or 'Irish' as 'white European'. After application of quality control criteria and
381 dropping participants who have withdrawn their consent, a total of 444,441 UKBB participants were
382 available for analysis with genotype and phenotype data.

383 We used only called or imputed genotypes and short insertions/deletions (here commonly referred to
384 as SNPs for simplicity) with a minor allele frequency (MAF) > 0.001%, imputation score >0.4 for
385 common (MAF≥0.5%) and >0.9 for rare (MAF<0.5%), within Hardy-Weinberg equilibrium ($p_{HWE}>10^{-15}$),
386 and minor allele count (MAC) > 10. This left us with 15,519,342 autosomal and X-chromosomal variants
387 for statistical analysis. GRCh37 was used as reference genome assembly.

388 ## Genome-wide association study

389 We performed genome-wide association studies for RP and primary RP using REGENIE v2.2.4 via a two-
390 step procedure to account for population structure as described in detail elsewhere[55]. We used a set
391 of high-quality genotyped variants (MAF>1%, MAC>100, missingness <10%, $p_{HWE}>10^{-15}$) in the first step
392 for individual trait predictions using the leave one chromosome out (LOCO) scheme. These predictions
393 were used in the second step as offset to run logistic regression models with saddle point
394 approximation to account for case/control imbalance and rare variant associations. Models were
395 adjusted for age, sex, genotyping batch, assessment centre, and the first ten genetic principal
396 components. We used a tier system to classify genome-wide significant loci. Given the absence of a
397 substantial replication cohort, we consider loci meeting a stringent p-value threshold of $p<1.0\times10^{-9}$ as
398 robust findings (tier 1) and further considered loci meeting the standard genome-wide significance
399 threshold of $p<5.0\times10^{-8}$ as strongly suggestive loci (tier 2).

400 ## LD score regression and genetic correlation to other common diseases

401 We tested for genomic inflation and calculated the SNP-based heritability using LD-score regression
402 (LDSC v1.0.1)[56]. We further used LDSC to compute genetic correlation between RP as well as primary
403 RP and a set of 20 preselected traits and diseases (**Supplementary Data 2**). P-values were corrected
404 for multiple testing by controlling the false-discovery rate at 5% according to the Benjamini-Hochberg
405 procedure. To explore genetic correlation with other common diseases, we computed genetic

406 correlation to a set of 185 phecodes (see below; **Supplementary Data 4**) with at least 1% SNP-based
407 heritability derived from the UKBB.

408 Signal selection and fine-mapping

409 We used regional clumping (±500kb) to select independent genomic regions associated with RP
410 treating the extended MHC region as a whole (chr6:25.5-34.0Mb) and collapsed neighbouring regions
411 using BEDtools v1.5.

412 Within each region, apart from the MHC region, we performed statistical fine-mapping using "Sum of
413 single effects" model (SuSiE)[57] as implemented in the R package *susieR* (v.0.11.92). Briefly, SuSiE
414 employs a Bayesian framework for variable selection in a multiple regression problem with the aim to
415 identify sets of independent variants each of which likely contains the true causally underlying genetic
416 variant. We implemented the workflow using default prior and parameter settings, apart from the
417 minimum absolute correlation, which we set to 0.1. Since SuSiE is implemented in a linear regression
418 framework, we used the GWAS summary statistics with a matching correlation matrix of dosage
419 genotypes instead of individual level data to implement fine-mapping (*susie_rss()*) as recommended
420 by the authors[57]. We computed the correlation matrix with LDstore v1.0.

421 Sex-specific SNP effect

422 We tested for a potential modulating effect of sex on SNP – RP association using an additional
423 interaction term in logistic regression models with the same adjustment set as described above. We
424 implemented this analysis in R v.4.1.2 using a set of 361,781 unrelated white European individuals.

425 Replication in East London Genes & Health

426 We performed a genome-wide association analysis of RP in the Genes & Health cohort of British
427 individuals of South Asian ancestry. We defined RP status using electronic health records and using the
428 same code list as for the European-ancestry cohort. We identified 401 RP cases and 40,131 controls
429 with complete covariate and genetic data passing quality control[30] (mean age at recruitment: 41.2 yrs
430 [s.d.D:14.2], 55.6% females).

431 Genotyping and quality control for Genes & Health is described in the Supplemental File 1. Briefly,
432 genotyping was done using the Illumina Infinium Global Screening Array v3 with additional multi-
433 disease variants and imputed to TopMed version 3 using the Michigan Imputation Server. We used
434 REGENIE[55] for association testing with age, sex, age^2, and the first twenty genetic principal components
435 as covariates. We included only autosomal genetic variants with a MAF>1% (in this cohort), INFO score
436 >0.7 for imputed variants, $p_{HWE}>10^{-10}$, and missingness < 10%. To allow for comparison with the results
437 from UK Biobank, we used the liftOver tool (v.2.0) to map between hg19 and hg38.

438 ## eQTL mapping to tissues/ Functional annotation

439 We systematically tested for a shared genetic signal between RP loci and gene expression levels (eQTL)
440 in 49 tissues from the GTEx project (v8)[22]. Briefly, we considered all protein coding genes or processed
441 transcripts encoded in a 1Mb window around RP loci and performed statistical colocalization[58] to test
442 for a shared genetic signal between RP and gene expression, as implemented in the R *coloc* package
443 (v.2.0). We only report RP loci – gene – tissue triplets with a posterior probability >80% for a shared
444 genetic signal as candidate causal genes. We adopted a recently recommended prior setting[59] with
445 $p_{12}=5x10^{-6}$. All GTEx variant-gene cis-eQTL associations from each tissue were downloaded in January
446 2020 from https://console.cloud.google.com/storage/browser/gtex-resources.

447 We further used the PrediXcan software[60] to associate genetically predicted expression levels of
448 *ADRA2A* with the risk of RP in 124 RP cases and 16,965 controls of the BioVU cohort[53].

449 ## Phenome wide association studies and variant look-up

450 We performed phenome-wide association studies for each RP locus identified using the
451 comprehensive electronic health record linkage to generate a set of 1,448 'phecodes', from which we
452 used 1,155 'phecodes' with a case number of more than 200. To generate phecode-based outcome
453 variables, we mapped ICD-10, ICD-9, Read version 2, Clinical Terms Version 3 (CTV3) terms codes from
454 self-report or medical health records, including cancer registry, death registry, hospitalization (e.g.,
455 Hospital Episode Statistics for England), and primary care, to a set of summarized clinical entities called
456 phecodes[61,62]. For example, more than 90 ICD-10 codes can indicate participants with type 1 diabetes
457 that are here collectively summarized under the phecode 'type 1 diabetes'[63]. We used any code that
458 was recorded, irrespective if it contributed to the primary cause of death or hospital admission, to
459 define phecodes. We adjusted all analyses for test centre to account for regional differences in coding
460 systems and case ascertainment. For each participant and phecode, we kept only the first entry
461 irrespective of the original data set, generating a first occurrence data set. We dropped codes that
462 were before or in the participants' birth year to minimize coding errors from electronical health
463 records. We implemented the same logistic regression framework used for sex-interaction testing
464 among unrelated individuals of White European ancestry. We applied a stringent Bonferroni correction
465 to account for multiple testing ($p< 3.7x10^{-5}$).

466 We further performed look-ups for all independent lead variants and proxies ($r^2>0.6$) associated with
467 RP in the OpenTargets database[21] and the GWAS catalog[20] (download: 27/04/2022) to search for
468 possibly previously reported traits and to establish novelty.

LCV analysis

To assess the evidence for a causal relationship between RP and each of the genetically correlated phenotypes (**Supplementary Data 3 and 4**) we implemented a latent causal variable (LCV) model[31]. The LCV model estimates a parameter termed genetic causality proportion (GCP). The values of GCP ranges from -1 to 1, quantifying both magnitude and direction of genetic causality between two traits. Briefly, the LCV model fits an unobserved latent variable, L, which mediates the genetic correlation between two traits, and compares the correlation of each trait with L to estimate the GCP. A |GCP| value of one indicates full genetic causality (suggestive for vertical pleiotropy) whereas a GCP value of zero implies no evidence for genetic causality (suggesting that the genetic correlation between two traits is likely to be mediated by horizontal pleiotropy or shared risk factors) and |GCP| < 1 indicates partial genetic causality between two traits. Negative values of GCP estimate suggest that RP lies downstream of the other trait and interventions on the other trait are likely to affect RP, while positive GCP values indicate that the other trait lies downstream of RP. We implemented LCV analysis using standard parameters with version 1.0. We used the same LD-scores as in the genetic correlation analysis and excluded the extended MHC regions from any calculations. We considered the number of significant genetic correlation as testing burden for LCV results.

Drug target annotation

To identify putative druggable targets for RP and test for evidence for drugs already in clinical trials, we queried the Open Target database[21] for all genes likely linked to GWAS loci (i.e., evidence from eQTL annotation or intronic). We augmented this gene list by functionally validated interaction partners from the SIGNOR network[32] and retained all matching drugs for further investigation. We lastly manually screened all prioritized drugs to match mechanisms to signs and symptoms of RP.

Data availability

All individual level data is publicly available to bona fide researchers from the UK Biobank (https://www.ukbiobank.ac.uk/) or Genes & Health study (https://www.genesandhealth.org/). GWAS summary statistics have been deposited at the GWAS Catalog (accession codes: GCST90271713 and GCST90271714). Lookups and druggable targets were derived from the GWAS Catalog https://www.ebi.ac.uk/gwas/ and the OpenTargets Genetics data base (https://genetics.opentargets.org/).

Code availability

Associated code and scripts for the analysis are available on Github[64] (https://github.com/pietznerm/gwas_rp).

References

1. Hughes, M. *et al.* Prediction and impact of attacks of Raynaud'S phenomenon, as judged by patient perception. *Rheumatol. (United Kingdom)* **54**, 1443–1447 (2015).

2. De Angelis, R., Salaffi, F. & Grassi, W. Health-Related Quality of Life In Primary Raynaud Phenomenon. *JCR J. Clin. Rheumatol.* **14**, 206–210 (2008).

3. Fábián, B., Csiki, Z. & Bugán, A. Raynaud-szindrómás betegek életminőségének jellemzői. *Orv. Hetil.* **159**, 636–641 (2018).

4. Wigley, F. M. & Flavahan, N. A. Raynaud's Phenomenon. *N. Engl. J. Med.* **375**, 556–565 (2016).

5. Rirash, F. *et al.* Calcium channel blockers for primary and secondary Raynaud's phenomenon. *Cochrane Database Syst. Rev.* **2017**, (2017).

6. Belch, J. *et al.* ESVM guidelines – the diagnosis and management of Raynaud's phenomenon. *Vasa* **46**, 413–423 (2017).

7. Su, K. Y. C. *et al.* Vasodilators for primary Raynaud's phenomenon. *Cochrane Database Syst. Rev.* **2021**, (2021).

8. Ennis, D., Ahmad, Z., Anderson, M. A. & Johnson, S. R. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon. *Best Pract. Res. Clin. Rheumatol.* **35**, 101684 (2021).

9. Cherkas, L. F. *et al.* Heritability of Raynaud's phenomenon and vascular responsiveness to cold: A study of adult female twins. *Arthritis Care Res.* **57**, 524–528 (2007).

10. Hur, Y. M. *et al.* Feeling of cold hands and feet is a highly heritable phenotype. *Twin Res. Hum. Genet.* **15**, 166–169 (2012).

11. Smyth, A. E., Hughes, A. E., Bruce, I. N. & Bell, A. L. A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon. *Rheumatology* **38**, 1094–1098 (1999).

12. Shemirani, A. H. *et al.* Polymorphism of clotting factors in Hungarian patients with Raynaud's. *Blood Coagul. Fibrinolysis* **22**, 56–59 (2011).

13. Susol, E. *et al.* A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. *Arthritis Rheum.* **43**, 1641–1646 (2000).

14. Munir, S., Freidin, M. B., Brain, S. & Williams, F. M. K. Association of raynaud's phenomenon with a polymorphism in the NOS1 gene. *PLoS One* **13**, 1–8 (2018).

15. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

16. Zhang, X. & Sun, Y. The predictive role of adra2a rs1800544 and htr3b rs3758987 polymorphisms in motion sickness susceptibility. *Int. J. Environ. Res. Public Health* **18**, (2021).

17. Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D. & Flavahan, N. A. Silent α(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. *Am. J. Physiol. - Hear. Circ. Physiol.* **278**, 1075–1083 (2000).

18. Freedman, R. R., Sabharwal, S. C., Desai, N., Wenig, P. & Mayes, M. Increased α-Adrenergic responsiveness in idiopathic raynaud's disease. *Arthritis Rheum.* **32**, 61–65 (1989).

19. Freedman, R. R., Moten, M., Migaly, P. & Mayes, M. Cold-induced potentiation of α2-adrenergic vasoconstriction in primary raynaud's disease. *Arthritis Rheum.* **36**, 685–690 (1993).

545 20. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
546 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–D1012
547 (2019).

548 21. Ochoa, D. *et al.* Open Targets Platform: Supporting systematic drug-target identification and
549 prioritisation. *Nucleic Acids Res.* **49**, D1302–D1310 (2021).

550 22. Consortium, G. The GTEx Consortium atlas of genetic regulatory effects across human tissues
551 The GTEx Consortium* Downloaded from. (2021).

552 23. Küster, M. M. *et al.* Epigenetic inactivation of the tumor suppressor IRX1 occurs frequently in
553 lung adenocarcinoma and its silencing is associated with impaired prognosis. *Cancers (Basel).*
554 **12**, 1–20 (2020).

555 24. Aoki, A. *et al.* SNPs on chromosome 5p15.3 associated with myocardial infarction in Japanese
556 population. *J. Hum. Genet.* **56**, 47–51 (2011).

557 25. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes.
558 *Nat. Genet.* **53**, 1415–1424 (2021).

559 26. Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify
560 distinct and shared genetic risk loci for coronary artery disease. *Nat. Genet.* **52**, 1169–1177
561 (2020).

562 27. Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* **182**,
563 1214-1231.e11 (2020).

564 28. Chen, M. H. *et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals*
565 *from 5 Global Populations*. *Cell* vol. 182 (2020).

566 29. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes for
567 coronary artery disease in over a million participants. *medRxiv* 2021.05.24.21257377 (2021)
568 doi:10.1101/2021.05.24.21257377.

569 30. Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community-based
570 population genomics and health study in British Bangladeshi and British Pakistani people. *Int.*
571 *J. Epidemiol.* **49**, 20-21i (2020).

572 31. O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52
573 diseases and complex traits. *Nat. Genet.* **50**, 1728–1734 (2018).

574 32. Licata, L. *et al.* SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update. *Nucleic*
575 *Acids Res.* **48**, D504–D510 (2020).

576 33. Edwards, J. M., Phinney, E. S., Taylor, L. M., Keenan, E. J. & Porter, J. M. α2-Adrenergic
577 receptor levels in obstructive and spastic Raynaud's syndrome. *J. Vasc. Surg.* **5**, 38–45 (1987).

578 34. Flavahan, N. A. A vascular mechanistic approach to understanding Raynaud phenomenon.
579 *Nat. Rev. Rheumatol.* **11**, 146–158 (2015).

580 35. Herrick, A. L. *et al.* A double-blind, randomized, placebo-controlled crossover trial of the α2c-
581 adrenoceptor antagonist orm-12741 for prevention of cold-induced vasospasm in patients
582 with systemic sclerosis. *Rheumatol. (United Kingdom)* **53**, 948–952 (2014).

583 36. Gyires, K., Zádori, Z. S., Török, T. & Mátyus, P. α2-Adrenoceptor subtypes-mediated
584 physiological, pharmacological actions. *Neurochem. Int.* **55**, 447–453 (2009).

585 37. Hunter, J. C. *et al.* Assessment of the role of α2-adrenoceptor subtypes in the antinociceptive,
586 sedative and hypothermic action of dexmedetomidine in transgenic mice. *Br. J. Pharmacol.*
587 **122**, 1339–1344 (1997).

588 38. Cooke, J. P. *et al.* Role of digital artery adrenoceptors in Raynaud's disease. *Vasc. Med.* **2**, 1–7
589 (1997).

590 39. Freedman, R. R., Baer, R. P. & Mayes, M. D. Blockade of vasospastic attacks by alpha 2-
591 adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. *Circulation*
592 **92**, 1448–51 (1995).

593 40. Johnson, S., Iazzetta, J. & Dewar, C. Severe Raynaud's Phenomenon with Yohimbine Therapy
594 for Erectile Dysfunction. *J. Rheumatol.* **30**, 2503–2505 (2003).

595 41. Sandler, B. & Aronson, P. Yohimbine-induced cutaneous drug eruption, progressive renal
596 failure, and lupus-like syndrome. *Urology* **41**, 343–345 (1993).

597 42. Varadi, D. P. & Lawrence, A. M. Suppression of Raynaud's Phenomenon by Methyldopa. *Arch.*
598 *Intern. Med.* **124**, 13–18 (1969).

599 43. Guo, X. *et al.* Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. *Oncogene*
600 **29**, 3908–20 (2010).

601 44. Gomez, I., Foudi, N., Longrois, D. & Norel, X. The role of prostaglandin E2 in human vascular
602 inflammation. *Prostaglandins Leukot. Essent. Fat. Acids* **89**, 55–63 (2013).

603 45. Ren, J., Karpinski, E. & Benishin, C. G. Prostaglandin E2 contracts vascular smooth muscle and
604 inhibits potassium currents in vascular smooth muscle cells of rat tail artery. *J. Pharmacol.*
605 *Exp. Ther.* **275**, 710–9 (1995).

606 46. Marceau, F. & Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. *Nat. Rev. Drug*
607 *Discov.* **3**, 845–52 (2004).

608 47. Freedman, R. R., Girgis, R. & Mayes, M. D. Abnormal responses to endothelial agonists in
609 Raynaud's phenomenon and scleroderma. *J. Rheumatol.* **28**, 119–21 (2001).

610 48. Bedarida, G., Kim, D., Blaschke, T. F. & Hoffman, B. B. Venodilation in Raynaud's disease.
611 *Lancet (London, England)* **342**, 1451–4 (1993).

612 49. Rosengren, A. H. *et al.* Overexpression of alpha2A-adrenergic receptors contributes to type 2
613 diabetes. *Science* **327**, 217–20 (2010).

614 50. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular
615 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat. Genet.* **52**,
616 680–691 (2020).

617 51. Morrison, S. F. Differential control of sympathetic outflow. *Am. J. Physiol. Regul. Integr. Comp.*
618 *Physiol.* **281**, R683-98 (2001).

619 52. Carnovale, C. *et al.* Beta-blocker-associated hypoglycaemia: New insights from a real-world
620 pharmacovigilance study. *Br. J. Clin. Pharmacol.* **87**, 3320–3331 (2021).

621 53. Gamazon, E. R. *et al.* Using an atlas of gene regulation across 44 human tissues to inform
622 complex disease- and trait-associated variation. *Nat. Genet.* **50**, 956–967 (2018).

623 54. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide
624 Range of Complex Diseases of Middle and Old Age. *PLoS Med.* **12**, 1–10 (2015).

625 55. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
626 binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

627 56. Bulik-sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in
628 genome-wide association studies. *Nat. Publ. Gr.* **47**, (2015).

629 57. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
630 selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B Stat.*
631 *Methodol.* **82**, 1273–1300 (2020).

632 58. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
633 Association Studies Using Summary Statistics. *PLoS Genet.* **10**, (2014).

634 59. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation
635 analyses. *PLoS Genet.* **16**, 1–20 (2020).

636 60. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference
637 transcriptome data. **47**, (2015).

638 61. Denaxas, S. *et al.* Mapping the Read2/CTV3 controlled clinical terminologies to Phecodes in
639 UK Biobank primary care electronic health records: implementation and evaluation. *AMIA ...*
640 *Annu. Symp. proceedings. AMIA Symp.* **2021**, 362–371 (2021).

641 62. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to phecodes: Workflow development and
642 initial evaluation. *JMIR Med. Informatics* **7**, 1–13 (2019).

643 63. Bastarache, L. Using Phecodes for Research with the Electronic Health Record: From PheWAS
644 to PheRS. *Annu. Rev. Biomed. Data Sci.* **4**, 1–19 (2021).

645 64. Hartmann, S. *et al.* ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon.
646 *Zenodo* (2023) doi:10.5281/zenodo.8082736.

647

648

Acknowledgement

All research related to UK Biobank has been done under the application number 44448. Mu. P. wishes to thank the MRC (MR/L006758/1, MR/V033867/1) and NIHR (NIHR202349) for support. This collaboration is part of the National Institute For Health Barts Biomedical Research Centre portfolio. BMJ is funded by a Medical Research Council (MRC) Clinical Research Training Fellowship (CRTF) jointly supported by the UK MS Society (BMJ; grant reference MR/V028766/1), and by Barts Charity.

The authors acknowledge the Scientific Computing of the IT Division at the Charité - Universitätsmedizin Berlin for providing computational resources that have contributed to the research results reported in this paper (https://www.charite.de/en/research/research_support_services/research_infrastructure/science_it/#c30646061).

Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017, MR/X009777/1), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc.

We thank Social Action for Health, Centre of The Cell, members of our Community Advisory Group, and staff who have recruited and collected data from volunteers. We thank the NIHR National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry Centre (King's College London), Wellcome Sanger Institute, and Broad Institute for sample processing, genotyping, sequencing and variant annotation. We thank: Barts Health NHS Trust, NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking and Dagenham), East London NHS Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, Public Health England (especially David Wyllie), Discovery Data Service/Endeavour Health Charitable Trust (especially David Stables), NHS Digital - for GDPR-compliant data sharing backed by individual written informed consent. Most of all we thank all of the volunteers participating in Genes & Health.

Author contributions

Conceptualization: Ma. P, CL
Data curation/Software: SH, SY, BMJ, SD, Ma. P
Formal Analysis: SH, SY, BMJ, EG, Ma. P

683 Methodology: SD, Ma. P
684 Visualization: SH, SY, Ma. P
685 Funding acquisition: CL, HH
686 Project administration: CL, HH
687 Supervision: Ma. P, CL
688 Writing – original draft: SH, Ma. P, CL
689 Writing – review & editing: SY, BMJ, SD, HH, Mu. P, MC
690

691 ## Competing Interests

692 Mu. P. has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme
693 (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis); and a PhD studentship jointly funded by
694 EPSRC and Astra Zeneca. Mu. P. also has unrestricted educational grant support for the UK
695 Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb. Mu. P. has developed
696 an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of
697 the IMI Consortium ARDAT (www.ardat.org). None of the funding outlined above is related to the
698 current paper. None of the other authors have a competing interests.

699

Genes & Health Research Team

Jacobs Benjamin M[2]

[2]Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK